» Articles » PMID: 17261650

Epidemiology and Cause-specific Outcome of Hypertrophic Cardiomyopathy in Children: Findings from the Pediatric Cardiomyopathy Registry

Overview
Journal Circulation
Date 2007 Jan 31
PMID 17261650
Citations 126
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Current information on the epidemiology and outcomes of hypertrophic cardiomyopathy (HCM) in children is limited by disease diversity and small case series.

Methods And Results: The Pediatric Cardiomyopathy Registry has collected prospective and retrospective data on children diagnosed with HCM since 1990. We identified the various causes of HCM in childhood and determined the relationship between outcomes, cause, and age at presentation. Of 855 patients <18 years of age with HCM, 8.7% (n=74) had inborn errors of metabolism, 9.0% (n=77) had malformation syndromes, 7.5% (n=64) had neuromuscular disorders, and 74.2% (n=634) had idiopathic HCM. Children with HCM associated with inborn errors of metabolism and malformation syndromes have significantly worse survival than the other 2 groups. Patients with idiopathic HCM diagnosed before 1 year of age (n=227) had worse survival from the time of diagnosis than those diagnosed after 1 year of age (n=407). Patients with idiopathic HCM who survived to at least 1 year of age, however, had an annual mortality rate of 1% that was similar regardless of whether they were diagnosed before or after 1 year of age.

Conclusions: In children, HCM is a diverse disorder with outcomes that depend largely on cause and age. Patients presenting before 1 year of age have the broadest spectrum of causes and the poorest outcome. In those children with idiopathic HCM who survive beyond age 1, however, survival is independent of age at diagnosis, with an annual mortality rate (1%) that is much lower than previously reported in children and is not different from has been found in population-based studies in adults.

Citing Articles

Contribution of hypoxia-inducible factor 1alpha to pathogenesis of sarcomeric hypertrophic cardiomyopathy.

Raj Murthi S, Petry A, Shashikadze B, Stockl J, Schmid M, Santamaria G Sci Rep. 2025; 15(1):2132.

PMID: 39820339 PMC: 11739497. DOI: 10.1038/s41598-025-85187-9.


Mortality from Hypertrophic Cardiomyopathy in Brazil-Historical Series.

Santos E, Castro P, Lima L, Pimentel J, Kuhn G, Sousa A Int J Environ Res Public Health. 2024; 21(11).

PMID: 39595765 PMC: 11594158. DOI: 10.3390/ijerph21111498.


Nonfatal Isolated Cardiac Nonlysosomal Glycogenosis: A Rare Cause of Infantile Hypertrophic Cardiomyopathy.

Deshaies C, Sett S, Penney L, Dhillon S CJC Pediatr Congenit Heart Dis. 2024; 3(4):178-181.

PMID: 39493669 PMC: 11524951. DOI: 10.1016/j.cjcpc.2024.02.003.


Cardiomyopathies in 100,000 genomes project: interval evaluation improves diagnostic yield and informs strategies for ongoing gene discovery.

Josephs K, Seaby E, May P, Theotokis P, Yu J, Andreou A Genome Med. 2024; 16(1):125.

PMID: 39472908 PMC: 11520845. DOI: 10.1186/s13073-024-01390-9.


Cardiomyopathy in Children and Adolescents in the Era of Precision Medicine.

Torbey A, Couto R, Grippa A, Maia E, Miranda S, Santos M Arq Bras Cardiol. 2024; 121(9):e20230154.

PMID: 39442130 PMC: 11634207. DOI: 10.36660/abc.20230154.